NewLink Genetics Corporation (NLNK) : During the past 4 weeks, traders have been relatively bearish on NewLink Genetics Corporation (NLNK), hence the stock is down -9.14% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -5.6% relative to the S&P 500. The 4-week change in the price of the stock is -8.79% and the stock has fallen -5.63% in the past 1 week.
NewLink Genetics Corporation has dropped 1.57% during the last 3-month period . Year-to-Date the stock performance stands at -72.36%. The stock has recorded a 20-day Moving Average of 6.35% and the 50-Day Moving Average is 7.4%.
NewLink Genetics Corporation (NASDAQ:NLNK): The stock opened at $10.19 on Friday but the bulls could not build on the opening and the stock topped out at $10.38 for the day. The stock traded down to $9.96 during the day, due to lack of any buying support eventually closed down at $10.06 with a loss of -1.85% for the day. The stock had closed at $10.25 on the previous day. The total traded volume was 177,151 shares.
Also, Stifel Nicolaus maintains their rating on the shares of NewLink Genetics Corporation (NASDAQ:NLNK). The current rating of the shares is Buy. Equity Analysts at the Firm lowers the price target to $22 per share from $23 per share. The rating by the firm was issued on August 1, 2016.
NewLink Genetics Corporation (NewLink) is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio includes both biologic and small-molecule immunotherapy product candidates. Its biologic product candidates are based on its HyperAcute immunotherapy technology, which is designed to stimulate the human immune system. Its small-molecule product candidates are focused on breaking the immune systems tolerance to cancer by inhibiting the indoleamine-(2, 3)-dioxygenase (IDO) pathway. Its lead product candidate algenpantucel-L or HyperAcute Pancreas. HyperAcute Pancreas is being studied in two Phase III clinical trials; one in surgically-resected pancreatic cancer patients that is being performed under a Special Protocol Assessment (SPA) with the United States Food and Drug Administration (FDA) and one in patients with locally advanced pancreatic cancer.